Saturday, 21 November 2026 Tracking Indian retail every day
Healthcare

Wipro GE Healthcare picks Rao to lead South Asia from 2027

A two-decade company insider takes both the Wipro GE Healthcare MD role and the GE HealthCare South Asia CEO mandate from 4 January 2027, succeeding Chaitanya Sarawate.

Wipro GE Healthcare picks Rao to lead South Asia from 2027

The short answer

Wipro GE Healthcare has named VS Raghavendra Rao as its managing director and president and CEO of GE HealthCare South Asia, effective 4 January 2027. Rao, a company veteran since 2002, succeeds Chaitanya Sarawate. The dual mandate keeps India and South Asia under one leader and signals continuity on localisation, innovation and access.

Key takeaways

  • Wipro GE Healthcare has appointed VS Raghavendra Rao as managing director and president and CEO of GE HealthCare South Asia, effective 4 January 2027.
  • Rao succeeds Chaitanya Sarawate, who leaves GE HealthCare after 16 years with the company across regional and global roles.
  • Rao joined Wipro GE Healthcare in 2002 and has held leadership roles across commercial and operational functions for more than two decades.
  • Rao will report to Rishad Premji, chairman of Wipro GE Healthcare, and Catherine Estrampes, chief commercial and growth officer at GE HealthCare.
  • The company said Rao's focus will be deeper localisation, faster innovation and wider access to quality care in India and South Asia.

Wipro GE Healthcare has picked VS Raghavendra Rao as managing director, with a parallel mandate as president and CEO of GE HealthCare South Asia, both effective 4 January 2027. The company said in a statement that Rao succeeds Chaitanya Sarawate, who is leaving to pursue other opportunities.

Rao is not an outside hire. He joined the business in 2002 and has spent more than two decades inside it, with extensive commercial and operational leadership experience. The appointment puts a known quantity in charge of both the India joint venture and GE HealthCare's wider South Asian operations.

The Wipro GE Healthcare MD job now carries a regional brief as well. Rao will report to Rishad Premji, chairman of Wipro GE Healthcare, and to Catherine Estrampes, chief commercial and growth officer at GE HealthCare. Two reporting lines, two mandates, one person. The dual reporting reflects the joint venture's two parents. That structure tells you how the parent companies view India: not just a sales territory, but a base for manufacturing and engineering that serves other markets too.

What does the leadership change signal for India's medical devices market?

Continuity, mostly. The company's own brief for Rao lists three priorities: deeper localisation, faster innovation and wider access to quality care. Those are the same themes Sarawate was credited with pushing during his tenure, which the company says spanned 16 years across regional and global roles.

Localisation is the phrase to watch. For medical device and diagnostics companies in India, it usually means manufacturing or assembling equipment locally, building supplier chains and adapting products to Indian price points and hospital workflows. It is a cost and speed argument as much as a policy one. Industry observers and media reports suggest public and private hospitals increasingly weigh local service networks and spare-part availability when they write tenders, not just the sticker price of a scanner or an ultrasound machine.

Premji framed the appointment around that base. Wipro GE Healthcare, he said, has built an enduring presence in India, and Rao's grasp of the business, customers and market puts him in position to extend it. Estrampes went further, calling India and South Asia strategically important to GE HealthCare "both as growth markets and as sources of innovation and manufacturing capabilities for the world."

That second half matters more than it sounds. If India is a source of innovation and manufacturing for GE HealthCare globally, then the South Asia CEO is also an internal supplier to the rest of the group. That gives the India operation more weight in global product decisions, and gives Indian hospitals earlier access to equipment designed with their constraints in mind.

What does this mean for hospital procurement teams?

On the face of it, little changes on 5 January. Leadership transitions at this level rarely move price lists or tender terms overnight. What does shift is the relationship layer. As background, large hospital chains and diagnostic networks typically negotiate multi-year equipment contracts, service-level agreements and software bundles with the top two or three vendors. A new MD with two decades of customer-side experience will be expected to protect those relationships.

Procurement heads should read the localisation push as a hint about where service and support investment will go. For hospital operators, the practical questions are:

  • Will local manufacturing shorten equipment delivery and service turnaround times?
  • Do software and diagnostics bundles get priced for mid-tier and tier-2 hospitals, not just large chains?
  • Will service contracts be structured around uptime guarantees as competition intensifies?

None of these is confirmed by the company. They are the natural tests of a localisation strategy, and they are what buyers will judge Rao on over the next year.

Why the dual India and South Asia mandate matters

Wipro GE Healthcare operates across medical technology, diagnostics and digital solutions. The joint venture structure, with Wipro and GE HealthCare as partners, gives the India business a hybrid character: local market knowledge on one side, global product lines on the other.

Holding the MD role and the South Asia CEO role together removes a layer between the India business and the regional mandate. That should speed up decisions on which products get launched where, and which markets in the neighbourhood get served from Indian capacity. It also means one leader is accountable when India's priorities and South Asia's priorities compete for the same inventory or the same engineering resources.

This is not a small point for a company whose chairman sits on the Wipro side and whose growth officer sits on the GE HealthCare side. Rao reports to both. The dual mandate gives him the standing to manage that matrix rather than be caught inside it.

What does the transition say about talent inside the joint venture?

Sarawate leaves after 16 years with GE HealthCare, and the company credits him with strengthening market leadership while advancing localisation, innovation and access. He also, per the company, championed India's growing role in GE HealthCare's global innovation, engineering and manufacturing network.

Replacing him with an internal executive who has been in the business since 2002 sends a clear message to the organisation. The company describes the appointment as reflecting the depth of leadership within Wipro GE Healthcare. For employees and mid-level managers, that is a promotion signal worth noting: the top job went to someone grown inside the system, not imported.

Estrampes said Rao brings "a rare combination of deep market understanding, trusted customer relationships and the ability to turn strategy into sustained business impact." The emphasis on execution, not strategy, is telling. The company is not looking for a reset.

What to watch next

The first signals will come quietly, not in a press release. Watch for announcements on local manufacturing capacity, new product introductions aimed at mid-tier hospitals, and partnerships with health-tech and diagnostics players. The company said Rao's focus will be on localisation, innovation and access. Each of those produces visible output: a new production line, a launch, a tie-up.

Second, watch the competitive response. India's medical devices and diagnostics market, as general background, is crowded with global majors and a growing set of domestic manufacturers. A leader with deep customer relationships and a localisation mandate could sharpen competition. Analysts suggest rivals may need to match on service depth, not just product specs.

Third, watch whether the dual mandate holds. If GE HealthCare later separates the India MD and South Asia CEO roles, that would signal a change in how the group weights the region. Until then, the structure is the strategy: one leader, one region, one localisation agenda, starting 4 January 2027.

Frequently asked questions

Who is the new MD of Wipro GE Healthcare?

VS Raghavendra Rao has been appointed managing director of Wipro GE Healthcare and president and CEO of GE HealthCare South Asia, effective 4 January 2027. He has been with the company since 2002 and succeeds Chaitanya Sarawate.

Who does the new Wipro GE Healthcare MD report to?

Rao reports to Rishad Premji, chairman of Wipro GE Healthcare Private Ltd, and to Catherine Estrampes, chief commercial and growth officer at GE HealthCare. The dual reporting reflects the joint venture's two parents.

Why is the Wipro GE Healthcare appointment significant?

The role combines the India joint venture leadership with a South Asia regional mandate, signalling that GE HealthCare treats India as both a growth market and a source of innovation and manufacturing for its global business.

What happened to Chaitanya Sarawate?

Sarawate is leaving GE HealthCare after 16 years across regional and global leadership roles to pursue external opportunities. The company credited him with strengthening market leadership and advancing localisation and access in India and South Asia.

Based on company announcements, filings and reporting by Free Press Journal, afaqs and Express Healthcare.

WiseRetail

The week in Indian retail, ecommerce and D2C — in one short email every Friday.